Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells
Salihanur Darici, Manuela Zavatti, Luca Braglia, et al.
Advances in Biological Regulation (2021) Vol. 82, pp. 100830-100830
Open Access | Times Cited: 11

Showing 11 citing articles:

Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia
Sven Stengel, Kevin Petrie, Yordan Sbirkov, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 2, pp. 338-348
Open Access | Times Cited: 19
Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
Gyung Hyuck Ko, Byeong-Bae Park, Jieun Uhm
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12708-12708
Open Access | Times Cited: 11
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 9
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells
Salihanur Darici, Heather G. Jørgensen, Xu Huang, et al.
Advances in Biological Regulation (2023) Vol. 89, pp. 100974-100974
Open Access | Times Cited: 2
Signaling pathways and regulation of gene expression in hematopoietic cells
Daniel Bogush, Joseph Schramm, Yali Ding, et al.
Advances in Biological Regulation (2022) Vol. 88, pp. 100942-100942
Open Access | Times Cited: 3
GAS2 Upregulation Is a Targetable Vulnerability in Chronic Myeloid Leukemia
Lizbeth A. Ramirez-Guzman, Wenjing Huang, John Cole, et al.
International Journal of Translational Medicine (2024) Vol. 4, Iss. 2, pp. 354-368
Open Access
Uncovering pre-sensitizing agents to FLT3 inhibitors in acute myeloid leukemia with ReSisTrace lineage tracing
Johanna Eriksson, Shuyu Zheng, Jie Bao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Advances in MDS/AML and inositide signalling
Alessia De Stefano, Maria Vittoria Marvi, Antonietta Fazio, et al.
Advances in Biological Regulation (2023) Vol. 87, pp. 100955-100955
Open Access | Times Cited: 1
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
Xiuqi Wang, Rosa Anna DeFilippis, Yuet‐Kin Leung, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 106966-106966
Open Access | Times Cited: 1
Strategies to overcome drug resistance in FLT3+ AML
Jingmei Yang
(2023)
Open Access
Page 1

Scroll to top